RxDoctor Payments Data

Michael Rosen, MD

Family Medicine · Penn Valley, PANPI 1285691659

Payments from drug & device makers

$188in general payments, 2019–2025

Across 8 payments — averaging $23.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$67
  • Aurinia Pharma U.S., Inc.$56
  • Sanofi$18
  • Genentech USA, Inc.$17
  • Lilly USA, LLC$16
  • Urovant Sciences Inc$14

What the payments were for

  • Food & beverage$188100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$188 in reported general payments places this provider in the 40th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$415,862
Medicare patients
470
Services billed
4,333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban865$261,026
SantylCollagenase Clostridium Hist.46$180,252
BiktarvyBictegrav/Emtricit/Tenofov Ala24$100,579
XifaxanRifaximin65$77,321
FarxigaDapagliflozin Propanediol221$67,869
DovatoDolutegravir Sodium/Lamivudine16$47,870
XareltoRivaroxaban159$45,813
EntrestoSacubitril/Valsartan106$38,306
NuedextaDextromethorphan Hbr/Quinidine42$35,314
Incruse ElliptaUmeclidinium Bromide86$28,865
TradjentaLinagliptin108$28,718
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$27,904
TivicayDolutegravir Sodium11$24,742
RenvelaSevelamer Carbonate33$22,812
JardianceEmpagliflozin63$21,344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$16$20,25028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Penn Valley

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →